Experience

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NovoCure Limited of $575 million aggregate principal amount of its 0.000%…

Davis Polk advised the underwriters in the initial public offering of JW (Cayman) Therapeutics Co. Ltd on the Hong Kong Stock Exchange and an international offering and listing in reliance…

Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the follow-on offering of 3,506,098 shares of common stock of Allakos Inc…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A/Regulation S offering by MPH Acquisition Holdings LLC, a wholly owned subsidiary of MultiPlan…

Davis Polk advised the joint book-running managers in connection with a $460 million SEC-registered common stock offering by Turning Point Therapeutics, Inc. The common stock is listed…

Davis Polk advised the representatives of the several underwriters in connection with Abcam plc’s $180 million U.S. initial public offering of 10,287,000 American depositary shares…

Davis Polk advised Xspray Pharma AB (publ) on a private placing of new shares. The private placing raised gross proceeds of approximately SEK 265 million.  Xspray was founded in 2003…

Davis Polk advised  the representatives of the several underwriters in connection with the $150 million initial public offering of 10,000,000 shares of common stock of Aligos…